Dr. Anton G. Henssen
Principal investigator and Pediatric Oncology Fellow,
Department of Pediatric Oncology and Hematology
Charité – University Hospital Berlin, Germany
Thema
„PGBD5 promotes site-specifi c concogenic mutations in human tumors“
Current Position
Since 12/2016 Principal investigator and Pediatric Oncology Fellow, Department of Pediatric Oncology and Hematology Charité - University Hospital Berlin, Germany
Work Experience and Post-Graduate Training
12/2013-12/2016 Research Fellowship, Pediatric Cancer Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
01/2012-12/2013 Residency, Pediatrics, University Children‘s Hospital Essen, Germany
06/2010-06/2011 Internship, Pediatrics, Hôpital Necker, Paris, France
Education
2007-2012 Doctoral Thesis, Neuroscience (Grade: 1.0)
RWTH Aachen, Aachen, Germany
2004-2011 Medical School, M.D. (Grade: 1.83),
University of Düsseldorf, Germany
2004 Abitur (High school, Grade: 1.2)
St. Ursula Gymnasium, Düsseldorf, Germany
Awards and Memberships
2018 Erna Brunner Prize
2017 Berlin Institute of Health (BIH) Paper of the month
2017 American Association for Cancer Research (AACR) Fellow-in-Training Award
2007 Human Brain Mapping Award
2017 German Cancer Consortium (DKTK) Investigator
since 2012 American Association of Cancer Research (AACR) member
since 2017 Advances in Neuroblastoma Research Association (ANRA) member
since 2017 Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)
Languages (fluent spoken and written)
English, German, French
Selected Presentations
Henssen, A.G. et al., Therapeutic targeting of PGBD5-induced DNA repair dependence in pediatric solid tumors, Oral presentation, AACR Annual Meeting, Washington D.C., USA, 2017
Henssen, A.G. et al., Targeting MYCN-driven transcription by BET-bromodomain inhibition. Oral presentation, AACR Annual Meeting, Philadelphia, USA, 2016
Henssen, A.G. et al., Human tumorigenesis induced by endogenous DNA transposase. Poster presentation, AACR Annual Meeting, Philadelphia, USA, 2015
Henssen, A.G. et al., BET protein inhibitor ,OTX015, has selective anti-tumoral activity in preclinical models of MYCN- amplified neuroblastoma. Poster presentation, AACR Annual Meeting, San Diego, USA, 2014
Peer-reviewed publications Publications (extract)
Henssen, A.G., Reed, C., Jiang, E., Dorado Garcia, H., von Stebut, J., MacArthur, I.C., Hundsdoerfer, P., Kim, J.H., de Stanchina, E., Kuwahara, Y., Hosoi, H., Ganem, N.J., Dela Cruz, F., Kung, A.L., Schulte, J.H., Petrini, J.H., Kentsis, A. Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors. Sci Transl Med, 2017 (IF 16.7)
Henssen, A.G., Koche, R. Zhuang J., Jiang E., Reed C., Eisenberg A., Still E., MacArthur I.C., Rodríguez-Fos E., Gonzalez S., Puiggròs M., Blackford A.N., Mason C.E., de Stanchina E., Gönen M., Emde A.K., Shah M., Arora K., Reeves C., Socci N.D., Perlman E., Antonescu C.R., Roberts C.W.M., Steen H., Mullen E., Jackson S.P., Torrents D., Weng Z., Armstrong, S.A. & Kentsis, A., PGBD5 promotes site-specific oncogenic mutations in human tumors, Nat. Genet. 2017 (IF 31.6)
Henssen, A.G., Odersky A., Szymansky A., Seiler M., Althoff K., Beckers A., Speleman F., Schäfers S., De Preter K., Astrahanseff K., Struck J., Schramm A., Eggert A., Bergmann A., Schulte J.H. Targeting tachykinin receptors in neuroblastoma. Oncotarget. 2016 (IF: 5.0)
Henssen, A. G., Jiang E., Zhuang J., Pinello L., Socci N.D., Koche R., Gonen M., Villasante C. M., Armstrong S. A., Bauer D. E., Weng Z., Kentsis A. . Forward genetic screen of human transposase genomic rearrangements. BMC Genomics 2016 (IF 3.8)
Sie haben Fragen?